Inhibition of pathogenic agents including α6β1 integrin receptor or α6β4 integrin receptor at a surface
patent number 7838000
Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes .alpha.6.beta.1 integrin receptors and/or .alpha.6.beta.4 integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therapeutic agents disclosed include a polypeptide comprising at least a portion of the G domain of the laminin-5 .alpha.3 chain that has been shown to bind .alpha.6.beta.1 integrin receptors and .alpha.6.beta.4 integrin receptors. In one embodiment, the therapeutic agents can be fused or chimeric materials in which the laminin-5 .alpha.3 chain polypeptide has been chemically bound to another material that can be useful in the destruction or neutralization of the pathogen.
Clemson University Research Foundation (Clemson, SC, US)